Date: 2012-04-05
Type of information: Fundraising
Company: Newron (Italy)
Investors: Zambon (Italy)
Amount: €20 million
Funding type: equity investment
Planned used:
Others: Newron Pharmaceuticals and Zambon have signed a strategic collaboration and licence option for safinamide. Under the agreement, Zambon will make an initial investment in Newron of 726,435 newly issued shares at market price for a fully diluted 9.1% shareholding. Zambon has also committed to increase its stake in Newron in a future share capital increase.
Therapeutic area: Neurodegenerative diseases
